Want to create an interactive transcript for this episode?
Podcast: PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Episode: Alexander Drilon, MD - Selective, Potent, Different: How to Enhance Clinical Benefits With Next-Generation ROS1 and TRK Inhibition in Treatment-Naïve and Pretreated NSCLC and Other Tumors
Description: Go online to PeerView.com/MVQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the latest advances with next-generation ROS1 and TRK inhibitors in treatment-naïve and pretreated ROS1 or NTRK fusion–positive NSCLC and other tumors, and provides practical, case-based guidance on how to incorporate these agents into management plans in the context of clinical practice and ongoing trials. Upon completion of this activity, participants should be better able to: Discuss the structure, characteristics, and mechanisms of action of novel tyrosine kinase inhibitors (TKI...